Adaptive (ADPT) Q3 2026 Earnings Call Transcript

Adaptive Biotechnologies reported Q3 2026 revenue of $83.9 million, up 39% year over year, and GAAP net income of $2.8 million, achieving total-company profitability ahead of expectations. MRD revenue was $72.6 million, with 44% growth excluding prior-year milestones; management raised full-year MRD revenue guidance to $276 million–$286 million and clinical volume growth guidance to approximately 42%. Growth and guidance were positive, though management does not anticipate GAAP net income or positive EPS for Q4 or the full year, and Medicare testing bundles are pressuring realized ASP.

Analysis

ADPT’s key debate is whether accelerating test adoption can translate into durable revenue per test—not whether demand exists. More frequent monitoring is a two-sided lever: it increases volume and clinical relevance, but the current Medicare bundle can dilute realized ASP as patients use tests beyond the covered allotment. The pending MolDX maintenance-bundle decision is therefore an economic catalyst, not merely a reimbursement headline. A smaller-than-expected bundle or a delay would leave growth increasingly dependent on volume and could cap margin and valuation upside.

The quarter’s profitability is a useful operating proof point, but not yet a reliable earnings run rate: management does not expect full-year GAAP profitability, and reported results include Pfizer-related Immune Medicine revenue and milestone timing. Treat the MRD backlog as visibility, not contracted near-term revenue; conversion and study timing can be lumpy, and its myeloma concentration creates exposure to one indication’s trial-design and regulatory trajectory. Management’s exclusivity and performance claims should be checked against independent clinical evidence and payer decisions.

Near term, the CMS rate correction and final 2027 rates can move sentiment; management argues the PLA issue should not flow through the Medicare episodic framework, but that remains an item to verify. Over 1–3 months, MolDX feedback and clinical-volume/ASP updates matter more than a single profitable quarter. Over 6–18 months, guideline adoption, serial testing workflows, and pharma study conversion could compound demand—if reimbursement keeps pace. Contrarian point: consensus may extrapolate volume growth while underweighting reimbursement friction; conversely, a MolDX expansion could make current ASP concerns look temporary.

Key Decisions for Investors

• ADPT: Favor a staged long rather than chasing the earnings reaction. Start after initial post-report volatility; reserve adds for a constructive MolDX update or evidence that ASP stabilizes as repeat testing rises. Upside is operating leverage plus broader reimbursement; downside is volume growth without adequate payment, which weakens revenue quality and valuation support.
• Use MolDX’s decision on the additional multiple-myeloma maintenance bundle and the finalized CMS rates as explicit risk gates. Reassess or reduce exposure if the bundle is denied/materially narrower than sought, or if realized ASP weakens while clinical-volume growth decelerates across subsequent quarters.
• Do not capitalize Q3 GAAP profitability as recurring earnings yet. Track MRD-only growth, realized ASP, sequencing gross margin, and operating cash flow separately from milestones and Immune Medicine; verify the planned Immune Medicine separation path before assigning standalone value.
• No direct PFE trade: the disclosed Pfizer-related payment is not enough to infer a material change in Pfizer’s outlook or a recurring commercial stream.